-
Medcap
- Gm
Aix-en-Provence
2016 - maintenant
-
Boehringer ingelheim
- Maghreb Medical Manager
Paris Cedex 13
2015 - maintenant
In charge of medical activities related to products prelaunch cross the Maghreb.(Advisory Boards,
communication plan cross all departments of oncology and pulmonology)
- 2 therapeutic areas Oncology and Respiratory
o Oncology: launch readiness for Giotrif® (Afatinib).
o Respiratory: Launch readiness for OFEV® (Nintadanib) on IPF (Idiopathic Pulmonary
Fibrosis) ➔ I have the opportunity to launch the initiative to create the National ILD
Network. The purpose is to gather experts from different areas of Algeria to promote
ILDs through scientific meetings / Multidisciplinary meetings / Exchanges via WEB
forums / Encourage publications on ILDs /
Managing 1 MSL, responsible to execute the communication plan in Oncology and Pulmonology
(Hospital presentations, CMEs, Medical Information & Experts managements).
Realizing slide kits (for new products and for sales force): slide kits needed for sales and medical
communication, they are regularly updated according to any new publications, guidelines. Adapted
to the purpose of marketing and medical strategies.
Promotional material validation for marketed products
In charge to support the marketing team in their medico-marketing events (briefing foreign
speakers and follow up and building scientific agendas).
Force of proposal in terms of CMEs concepts ( Introduce new innovative concept according to the
market background ex : CMEs around relationship between the physician and patients from
diagnosis to treatment follow up). Example: This concept fit a particular situation when we have
to organize a scientific meeting for specialists through their association and when those specialists
don't agree that one of them has to come and trained them. ``Very complex situation''. So my
proposition to the product manager is to engage one of them to report a patient case on paper
only or a slide kit which will be presented and facilitated by a psychologist not to develop the
clinical aspect but the communication between the patient and his physician on how to announce
the diagnosis, how the physician could insure the compliance from patient to the treatment and
how could be the optimized follow up with this patient.
Achievement: National Interstitial Lung Diseases (ILD) Network: gathering experts from public
and private area to engage them in a medical communication plan through national scientific
meetings and enhance multidisciplinary discussion for the benefit of ILD patients. This project
actually is ongoing for which we have obtained the engagement from experts (pulmonologist)
from the center and eastern region. A logo was designed to name this network and we listed the
objectives of this organization: Promotion of ILDs , creating ILDs dedicated consultation in every
pulmonology department, promote forums and clinical cases discussions through a WEB SITE.
Medical Manager (Oncology, Anti-infectious, GI)
-
Astra Zeneca
- Medical Director
Rueil-Malmaison
2014 - 2015
Organization and execution of launch symposium (ex: launch of Meronem® - anti-infectious. The
Agenda covered three aspects Bacteriology, clinic and pharmaco-economy).Successful symposium
translated by the engagement of the HCPs towards the product and the feedbacks from HCPs
about its concept as an example of Ethic and scientific event)
- Engaging experts from Pasteur Institute Bacteriology Department (Pr TALI-MAAMAR) to talk about
the risk of resistance coming from misuse of previously marketed antibiotic Imipenem from the
same family and give reminders on Antibiotics treatment good practice.
- Launch of EGFR Testing platform in Algeria with certification of the first pathology department
from EMQN Network. (Pr AMIR & Pr TERKI)
Sales force medical training in:
Oncology: Breast, Lung and prostate cancer. (ZOLADEX®, FASLODEX®, CASODEX®, IRESSA®)
GI: For Inexium® (EZOMEPRAZOLE)
Anti-infectious: Meronem® (MEROPENEM)
and periodic follow up and evaluation in medical knowledge for the sales force.
Trained on managing veeva vault platform to respond and track medical information requests.
Readiness plan : the launch of the national breast and lung cancer registry.
Medical Director
-
Ipsen
- Medical director
Boulogne-Billancourt
2012 - 2014
Responsible on 6 major therapeutic areas Oncology (Prostate Cancer), Gynecology (Endometriosis
& Fibroma), Endocrinology (Acromegaly & Neuroendocrine Tumors), Botulinum Toxin (Spasticity &
Dystonia) ,Primary care (Smecta®, Bedelix® and Forlax®).
Follow up and initiation of several investigational centers in registries and interventional
international trial.
Oncology (Prostate cancer):
Adapt the promotional material with medical messages according to the changing competitor
environment with the new comer ENANTON® from Takeda Company.
Releasing CME for urologists under the Umbrella of UROS Program with the participation of high
value foreign speaker (Pr Sharokh SHARIAT (815 publications) from VIENNA-AUSTRIA & Pr
Morgan ROUPRET (355 publications) from France) on prostate cancer, bladder cancer.
Gynecology: I create a label for a CME program which was integrated as an intercontinental CME
label within IPSEN called GYNIPS focused on the endometriosis for which I engage 3 international
experts based in France (Pr Charles CHAPRON, Pr Pietro SANTULLI & Dr Anne Elodie
MILLISCHER-BELLAICHE) recognized as the experts in endometriosis.
3 CME sessions was released with this team in 1 year and half, where several updates in the
endometriosis were shared with experts from Algeria which shows the added value of IPSEN as a
company investing in research and development in endometriosis.
Endocrinology:
Acromegaly: supporting the national network of Acromegaly / releasing CME sessions towards
and GPs to detect first symptoms of Acromegaly.
Neuroendocrine Tumors (NET): Pre launch activities to improve the awareness on the NET.
CMEs. Develop patient communication via releasing patient book with needed information and
advices.
Botulinum Toxin: Follow up of one interventional registry on the efficacy and safety of Botulinum
toxin with patients suffering from post-stroke spasticity (Functional Re-education and
Rehabilitation).
Engage 3 Algerian investigational centers in an international phase IV trial on Cervical Dystonia
(Neurologists)
Primary care: Follow up and validation of medical-marketing messages and promotional
materials.
Medical advisor & PV Deputy
-
Sanofi
- Medical Advisor
Paris
2008 - 2012
In charge of medical training for representatives in Oncology (Taxotere®, Eloxatine®), Transplantation
(Thymoglobuline), Hematology (FLUDARA®), Prostate adenoma (Xatral®), Allergic Rhinitis (Telfast®,
Nasacort®, Solupred®), Antibiotics (Tavanic® & Targocid®) and other OTC products.
The main therapeutic areas a have a consistent experience on training for reps are: Allergic rhinitis,
Prostate adenoma, oncology and antibiotics.
Promotional material validation
Respond to medical information requests from HCPs
Member of New Product Committee (Business development TASK FORCE): assessment of business
cases. That was about to provide medical opinion on the accuracy of new products proposed to be
developed taking in account any FDA warning and the local market environment.
In charge to release Oncology CMEs: Intensive Oncology Meeting (1 day & Half) 50 attendees engaging
local and foreign speakers. 3 sessions (3 years)
The purpose of this kind of CMEs is to join together oncologists as experts and rising stars to develop
around specific subjects scientific agenda not mandatory on therapeutic areas linked to the pharma
company drugs. The activities were arranged in 2 parts. The first one taking a one day duration for
experts to discuss the scientific updates and the second part was about to engage rising stars to discuss
clinical cases.
Launch symposium preparation (Targocid® & Tavanic®): Engaging speakers, medical briefing...
Pharmacovigilance:
Training representatives and other stakeholders partner of SANOFI in reporting PV Individual
Case Safety Report.
Investigation in two important cohort PV cases in two departments of oncology after a high
frequency incidence of adverse events some of them with fatal effect. My conclusion on these
investigations after following my recommendations leads the medical staff of these two department to
return to a normal frequency of adverse events and keep them aware of some mistakes done in terms of
preparation of cytotoxic infusion
Product Manager
-
Sanofi Aventis
- Product Manager
Paris
2005 - 2009
In charge to launch the institutional campaign for the generic brand of Sanofi ``Winthrop''
In charge of building and implementing the marketing strategy cross Algeria on Allergic Rhinitis
(Range of products: Telfast®, Nasacort® & Solupred®) .
Medical Representative
-
Médical Algérien IMA
- Medical Representative
2002 - 2004
Medical Representative
-
IMA
- Medical Representative
2000 - 2002
In charge to promote mature and products in launch.
-
Djilali BELKHENCHIR Hospital
- Pediatric ER physician
1999 - 2000
As a GP I was the first line doctor to manage the Pediatric ER with the help of a team of 2 trainee
physicians, one nurse, supported if any need by a specialist from the pediatric department.
This experience was help me to be trained as a physician in real life, meaning to be trained on
what the University can't do ``How to listen actively to the patients - To learn what is the specific
characteristics of pediatric medicine as an approach towards children and their parents and how
to optimize treatment and children care with the collaboration of their parents''.
Education and specific trainings
